You are here: Industry Insights > AstraZeneca

News List

Calquence Approved in EU for Chronic Lymphocytic Leukemia americanpharmaceuticalreview
November 18, 2020
AstraZeneca’s Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukemia (CLL), the most common type of leukemia in ..
Brilinta Approved to Reduce Stroke Risk americanpharmaceuticalreview
November 17, 2020
AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk ...
Calquence fails to prevent respiratory failure in COVID-19 patients europeanpharmaceuticalreview
November 16, 2020
AstraZenaca reveals Calquence (acalabrutinib) did not increase the proportion of hospitalised COVID-19 patients who remained alive and free of respiratory failure.
Forxiga Approved in the EU for Heart Failure americanpharmaceuticalreview
November 13, 2020
AstraZeneca’s Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D).
Amgen, AZ’s asthma drug tezepelumab scores phase III win pharmatimes
November 12, 2020
Amgen and AstraZeneca’s (AZ) experimental asthma drug tezepelumab has scored a phase III win in severe, uncontrolled asthma.
EU OK for AZ’s Calquence in CLL pharmatimes
November 11, 2020
The European Commission has approved AstraZeneca’s Calquence (acalabrutinib)for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).
US green lights AZ’s Brilinta to reduce risk of stroke pharmatimes
November 10, 2020
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Brilinta (ticagrelor) to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischaemic attack (TIA).
Australia to initiate manufacturing of vaccine candidate for Covid-19 pharmaceutical-technology
November 10, 2020
Australia is planning to commence the manufacturing of Covid-19 vaccine candidate, AZD1222, at biotech firm CSL’s advanced manufacturing facility in Broadmeadows, Victoria.
Lynparza scores two new EU approvals pharmatimes
November 09, 2020
AstraZeneca and MSD's immunotherapy Lynparza (olaparib) has scored two new approvals in the European Union.
OM Pharma and AstraZeneca Sign Collaboration Agreement contractpharma
November 09, 2020
OM Pharma and AstraZeneca finalized a strategic collaboration agreement today at a partnership signing ceremony in Shanghai.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page